Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme

BACKGROUND: Androgen suppression is a central component of prostate cancer management but causes substantial long-term toxicity. Transdermal administration of oestradiol (tE2) circumvents first-pass hepatic metabolism and, therefore, should avoid the cardiovascular toxicity seen with oral oestrogen...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Lancet
Auteurs principaux: Langley, Ruth E, Gilbert, Duncan C, Duong, Trinh, Clarke, Noel W, Nankivell, Matthew, Rosen, Stuart D, Mangar, Stephen, Macnair, Archie, Sundaram, Subramanian Kanaga, Laniado, Marc E, Dixit, Sanjay, Madaan, Sanjeev, Manetta, Caroline, Pope, Alvan, Scrase, Christopher D, Mckay, Stephen, Muazzam, Iqtedar A, Collins, Gerald N, Worlding, Jane, Williams, Simon T, Paez, Edgar, Robinson, Angus, McFarlane, Jonathan, Deighan, John V, Marshall, John, Forcat, Silvia, Weiss, Melanie, Kockelbergh, Roger, Alhasso, Abdulla, Kynaston, Howard, Parmar, Mahesh
Format: Artigo
Langue:Inglês
Publié: 2021
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7614681/
https://ncbi.nlm.nih.gov/pubmed/33581820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(21)00100-8
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires